Pneumovax 23 Vaccine Description
Merck's Pneumovax 23 (Pneumococcal Vaccine Polyvalent) is a vaccine that can help protect against infection by 23 types of pneumococcal bacteria, common and often cause serious illnesses.
Pneumovax 23 vaccine contains 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).
On October 23, 2020, a study published by PLOS concluded 'PPV23 vaccination provides moderate long-term protection against hospitalization with PPV23 serotype pneumonia. And, PPV23 vaccination may continue to have an important role in national pneumococcal immunization policies, including the possibility of revaccination of older adults.' In a group of 2,357 patients (717 PPV23 cases, 1,640 controls) with an average time of 10 years since PPV23 vaccination, we estimated the VE of PPV23 against PPV23 serotype pneumonia to be 24% after adjustment for patient factors (95% CI 5%–40%, p = 0.02).
Merck Sharp & Dohme Corp. is an American multinational pharmaceutical company and one of the world's largest pharmaceutical companies.
Pneumovax 23 Vaccine Indication
The global prevalence of the pneumococcal disease, an infection caused by Streptococcus pneumoniae, is evolving, says the U.S. CDC. Highly aggressive strains, or serotypes, threaten to put more people at risk for non-invasive pneumococcal illnesses such as pneumonia (when it is confined to the lungs), sinusitis, and otitis media (middle ear infection); and invasive pneumococcal illnesses such as bacteremia (infection in the bloodstream), bacteremic pneumonia (pneumonia with bacteremia) and meningitis.
The pneumococcal disease includes pneumococcal infections of the lung, blood, and coverings of the brain and spinal cord. Pneumovax 23 will not prevent disease caused by capsular pneumococcus types other than those contained in the vaccine.
Additionally, the U.S. CDC recommends Pneumovax 23 for people with certain chronic conditions such as diabetes, heart disease, or COPD and are 19 to 64 years old.
Do not administer PNEUMOVAX 23 to individuals with a history of a hypersensitivity reaction to any vaccine component.
Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.
Use caution and appropriate care in administering PNEUMOVAX 23 to individuals with severely compromised cardiovascular and/or pulmonary function in whom a systemic reaction would pose a significant risk.
Available human data from clinical trials of PNEUMOVAX 23 in pregnancy have not established the presence or absence of a vaccine-associated risk.
Since elderly individuals may not tolerate medical interventions as well as younger individuals, a higher frequency and/or greater severity of reactions in some older individuals cannot be ruled out.
Persons who are immunocompromised, including persons receiving immunosuppressive therapy, may have a diminished immune response to PNEUMOVAX 23.
Pneumovax 23 Vaccine Dosage
Pneumovax 23 is administered as an intramuscular or subcutaneous injection only.
Pneumovax 23 is for people 50 years of age and older and is approved for persons aged ≥2 years who are at increased risk for pneumococcal disease. And if you are 65 years or older, even if you already had a dose of another vaccine before 65 for pneumococcal pneumonia, the U.S. CDC recommends you get Pneumovax 23.
Pneumovax 23 Vaccine News
June 9, 2021 - As reported by Barron's the U.S. Food and Drug Administration approved Pfizer’s updated pneumococcal vaccine (Prevnar 20) for adults late Tuesday in a development that positions the drug giant for a battle with Merck as both hope to win supremacy in the lucrative market.
April 29, 2021 - Merck confirmed Pneumovax 23 sales decreased by 36% last year.
October 23, 2020 - A case-control test-negative design study: Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults. In establishing an established national childhood PCV13 vaccination program, PPV23 vaccination of clinical at-risk patient groups and adults aged ≥65 years provided moderate long-term protection against hospitalization with PPV23 serotype pneumonia. These findings suggest that PPV23 vaccination may continue to have an important role in adult pneumococcal vaccine policy, including the possibility of revaccination of older adults.
September 25, 2020 - The U.S. FDA approved Merck's request submitted and received November 26, 2019, to supplement your Biologics License Application under section 351(a) of the Public Health Service Act for Pneumococcal Vaccine, Polyvalent, PNEUMOVAX® 23 manufactured at your West Point, Pennsylvania facility to update the package insert to include data on the sequential administration of Prevnar 13® and PNEUMOVAX® 23 in Sections 6.1 Clinical Trials Experience and 14.2 Immunogenicity.
July 20, 2020 - Time for a third-generation pneumococcal conjugate vaccine.
June 22, 2020 - Merck announced results from two initial Phase 3 studies evaluating the safety, tolerability, and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine. These data, in addition to results from V110-029, a study evaluating PNEUMOVAX ® 23 in healthy adults 50 years of age or older, were published via the International Symposium on Pneumococci and Pneumococcal Diseases online digital library.
January 31, 2020 - Updated Pneumococcal Vaccine Recommendations for Older Adults.
November 26, 2019 - The U.S. FDA stated: 'We have approved your request submitted and received June 4, 2019, to supplement your Biologics License Application under section 351(a) of the Public Health Service Act for Pneumococcal Vaccine Polyvalent (PNEUMOVAX®23) manufactured at West Point, Pennsylvania. We hereby approve the draft package insert labeling submitted under Amendment 5001, dated November 8, 2019.'